Table 2.

Dates of FDA and EMA approval of PET radiopharmaceuticals used in breast cancer with the respective clinical indication and type of recommendation/document

PET radio pharmaceutical	FDA approval	EMA approval	Clinical indications	Type of recommendation (date of last update)
[18F]NaF	1972	2015 EMA/212874/2015	Bone metastases identification and treatment response assessment	EANM/SNMMI guideline (2015) 38 NCCN guidelines (2023) 10
2-[18F]FDG	2000 (for oncology)	2018 EMA/496103/2018	Whole-body Systemic staging of patients with clinical Stage IIB – IV Lesion detection when there is suspicion of recurrence Assessing response to treatment Breast-dedicated imaging MRI contraindication	Whole-body ESMO guidelines (2019) 6 ESTRO guidelines (2020) 39 ESMO guidelines (2021) 40 NCCN guidelines (2023) 10 EANM/SNMMI guideline being revised* Breast-dedicated imaging EANM/SNMMI guideline being planned*
[18F]FES (CeriannaTM )	2020	Not approved	Detection of ER-positive lesions in patients with recurrent or metastatic BC Patients selection for hormonal therapies	NCCN guidelines (2023) 10 EANM/SNMMI guideline being revised*

BC, breast cancer; PET, positron emission tomography.

*Some authors are participating in these guidelines.